Becton Dickinson Income from Continuous Operations 2010-2024 | BDX
Becton Dickinson annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Becton Dickinson income from continuous operations for the quarter ending December 31, 2024 was $0.303B, a 7.45% increase year-over-year.
- Becton Dickinson income from continuous operations for the twelve months ending December 31, 2024 was $1.726B, a 32.46% increase year-over-year.
- Becton Dickinson annual income from continuous operations for 2024 was $1.705B, a 11.44% increase from 2023.
- Becton Dickinson annual income from continuous operations for 2023 was $1.53B, a 6.42% decline from 2022.
- Becton Dickinson annual income from continuous operations for 2022 was $1.635B, a 1.93% increase from 2021.
Becton Dickinson Annual Income from Continuous Operations
(Millions of US $) |
| 2024 |
$1,705 |
| 2023 |
$1,530 |
| 2022 |
$1,635 |
| 2021 |
$1,604 |
| 2020 |
$352 |
| 2019 |
$1,233 |
| 2018 |
$311 |
| 2017 |
$1,100 |
| 2016 |
$977 |
| 2015 |
$695 |
| 2014 |
$1,185 |
| 2013 |
$929 |
| 2012 |
$1,110 |
| 2011 |
$1,201 |
| 2010 |
$1,115 |
| 2009 |
$1,167 |
Becton Dickinson Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-12-31 |
$303 |
| 2024-09-30 |
$399 |
| 2024-06-30 |
$487 |
| 2024-03-31 |
$537 |
| 2023-12-31 |
$282 |
| 2023-09-30 |
$153 |
| 2023-06-30 |
$407 |
| 2023-03-31 |
$461 |
| 2022-12-31 |
$509 |
| 2022-09-30 |
$287 |
| 2022-06-30 |
$390 |
| 2022-03-31 |
$390 |
| 2021-12-31 |
$568 |
| 2021-09-30 |
$-105 |
| 2021-06-30 |
$407 |
| 2021-03-31 |
$299 |
| 2020-12-31 |
$1,003 |
| 2020-09-30 |
$-394 |
| 2020-06-30 |
$286 |
| 2020-03-31 |
$183 |
| 2019-12-31 |
$277 |
| 2019-09-30 |
$163 |
| 2019-06-30 |
$451 |
| 2019-03-31 |
$20 |
| 2018-12-31 |
$599 |
| 2018-09-30 |
$-135 |
| 2018-06-30 |
$594 |
| 2018-03-31 |
$-12 |
| 2017-12-31 |
$-136 |
| 2017-09-30 |
$328 |
| 2017-06-30 |
$-133 |
| 2017-03-31 |
$344 |
| 2016-12-31 |
$561 |
| 2016-09-30 |
$20 |
| 2016-06-30 |
$390 |
| 2016-03-31 |
$338 |
| 2015-12-31 |
$229 |
| 2015-09-30 |
$182 |
| 2015-06-30 |
$62 |
| 2015-03-31 |
$216 |
| 2014-12-31 |
$235 |
| 2014-09-30 |
$301 |
| 2014-06-30 |
$326 |
| 2014-03-31 |
$287 |
| 2013-12-31 |
$271 |
| 2013-09-30 |
$91 |
| 2013-06-30 |
$292 |
| 2013-03-31 |
$276 |
| 2012-12-31 |
$270 |
| 2012-09-30 |
$275 |
| 2012-06-30 |
$312 |
| 2012-03-31 |
$275 |
| 2011-12-31 |
$249 |
| 2011-09-30 |
$254 |
| 2011-06-30 |
$322 |
| 2011-03-31 |
$311 |
| 2010-12-31 |
$314 |
| 2010-09-30 |
$232 |
| 2010-06-30 |
$294 |
| 2010-03-31 |
$285 |
| 2009-12-31 |
$304 |
| 2009-09-30 |
$260 |
| 2009-06-30 |
$339 |
| 2009-03-31 |
$259 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$66.130B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
